RS64778B1 - Lečenje raka - Google Patents
Lečenje rakaInfo
- Publication number
- RS64778B1 RS64778B1 RS20230615A RSP20230615A RS64778B1 RS 64778 B1 RS64778 B1 RS 64778B1 RS 20230615 A RS20230615 A RS 20230615A RS P20230615 A RSP20230615 A RS P20230615A RS 64778 B1 RS64778 B1 RS 64778B1
- Authority
- RS
- Serbia
- Prior art keywords
- erdafitinib
- treatment
- cancer
- phosphate levels
- serum phosphate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
- Laminated Bodies (AREA)
- Medicinal Preparation (AREA)
- Prostheses (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455211P | 2017-02-06 | 2017-02-06 | |
| EP17209098 | 2017-12-20 | ||
| EP18702299.1A EP3576740B1 (en) | 2017-02-06 | 2018-02-02 | Cancer treatment |
| PCT/EP2018/052694 WO2018141921A1 (en) | 2017-02-06 | 2018-02-02 | Cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS64778B1 true RS64778B1 (sr) | 2023-11-30 |
Family
ID=61094531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20230615A RS64778B1 (sr) | 2017-02-06 | 2018-02-02 | Lečenje raka |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11077106B2 (enExample) |
| EP (2) | EP3576740B1 (enExample) |
| JP (3) | JP2020505425A (enExample) |
| KR (2) | KR20250069693A (enExample) |
| CN (1) | CN110198716A (enExample) |
| AU (2) | AU2018216969B2 (enExample) |
| BR (1) | BR112019016043A2 (enExample) |
| CA (1) | CA3049737A1 (enExample) |
| DK (1) | DK3576740T3 (enExample) |
| ES (1) | ES2953005T3 (enExample) |
| FI (1) | FI3576740T3 (enExample) |
| HR (1) | HRP20230697T1 (enExample) |
| HU (1) | HUE062453T2 (enExample) |
| IL (1) | IL268463A (enExample) |
| JO (1) | JOP20190190A1 (enExample) |
| LT (1) | LT3576740T (enExample) |
| MX (2) | MX2019009304A (enExample) |
| PH (1) | PH12019501885A1 (enExample) |
| PL (1) | PL3576740T3 (enExample) |
| RS (1) | RS64778B1 (enExample) |
| SG (2) | SG10202105110VA (enExample) |
| SI (1) | SI3576740T1 (enExample) |
| SM (1) | SMT202300233T1 (enExample) |
| TW (1) | TWI874925B (enExample) |
| UA (1) | UA126336C2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113957146A (zh) | 2014-09-26 | 2022-01-21 | 詹森药业有限公司 | 使用fgfr突变基因组鉴定将对用fgfr抑制剂进行治疗有反应的癌症患者 |
| US20200208224A1 (en) * | 2014-09-26 | 2020-07-02 | Janssen Pharmaceutica Nv | Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor |
| JOP20190190A1 (ar) * | 2017-02-06 | 2019-08-04 | Janssen Pharmaceutica Nv | معالجة سرطان |
| PH12021551949A1 (en) * | 2019-02-12 | 2022-07-18 | Janssen Pharmaceutica Nv | Cancer treatment |
| SG11202109902SA (en) * | 2019-03-29 | 2021-10-28 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| SG11202109854RA (en) * | 2019-03-29 | 2021-10-28 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| JOP20220182A1 (ar) * | 2020-02-12 | 2023-01-30 | Janssen Pharmaceutica Nv | مثبطات كيناز تيروسين fgfr لعلاج سرطان المثانة الغازي غير العضلي عالي الخطورة |
| WO2021201201A1 (ja) * | 2020-04-03 | 2021-10-07 | インタープロテイン株式会社 | 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物 |
| WO2024241297A1 (en) * | 2023-05-24 | 2024-11-28 | Janssen Pharmaceutica Nv | Treatment of locally advanced or metastatic urothelial carcinoma with erdafinitib |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) * | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| JOP20190190A1 (ar) * | 2017-02-06 | 2019-08-04 | Janssen Pharmaceutica Nv | معالجة سرطان |
-
2017
- 2017-06-16 JO JOP/2019/0190A patent/JOP20190190A1/ar unknown
-
2018
- 2018-02-02 LT LTEPPCT/EP2018/052694T patent/LT3576740T/lt unknown
- 2018-02-02 KR KR1020257014703A patent/KR20250069693A/ko active Pending
- 2018-02-02 EP EP18702299.1A patent/EP3576740B1/en active Active
- 2018-02-02 RS RS20230615A patent/RS64778B1/sr unknown
- 2018-02-02 HU HUE18702299A patent/HUE062453T2/hu unknown
- 2018-02-02 US US16/483,579 patent/US11077106B2/en active Active
- 2018-02-02 FI FIEP18702299.1T patent/FI3576740T3/fi active
- 2018-02-02 ES ES18702299T patent/ES2953005T3/es active Active
- 2018-02-02 DK DK18702299.1T patent/DK3576740T3/da active
- 2018-02-02 CA CA3049737A patent/CA3049737A1/en active Pending
- 2018-02-02 JP JP2019541398A patent/JP2020505425A/ja not_active Withdrawn
- 2018-02-02 SG SG10202105110VA patent/SG10202105110VA/en unknown
- 2018-02-02 HR HRP20230697TT patent/HRP20230697T1/hr unknown
- 2018-02-02 MX MX2019009304A patent/MX2019009304A/es unknown
- 2018-02-02 SG SG11201907199QA patent/SG11201907199QA/en unknown
- 2018-02-02 CN CN201880008126.XA patent/CN110198716A/zh active Pending
- 2018-02-02 AU AU2018216969A patent/AU2018216969B2/en active Active
- 2018-02-02 KR KR1020197024552A patent/KR20190110581A/ko not_active Ceased
- 2018-02-02 EP EP23178682.3A patent/EP4286005A3/en active Pending
- 2018-02-02 SI SI201830961T patent/SI3576740T1/sl unknown
- 2018-02-02 BR BR112019016043-4A patent/BR112019016043A2/pt not_active Application Discontinuation
- 2018-02-02 UA UAA201909567A patent/UA126336C2/uk unknown
- 2018-02-02 TW TW112109467A patent/TWI874925B/zh active
- 2018-02-02 PL PL18702299.1T patent/PL3576740T3/pl unknown
- 2018-02-02 SM SM20230233T patent/SMT202300233T1/it unknown
-
2019
- 2019-08-04 IL IL268463A patent/IL268463A/en unknown
- 2019-08-05 PH PH12019501885A patent/PH12019501885A1/en unknown
- 2019-08-05 MX MX2022007955A patent/MX2022007955A/es unknown
-
2021
- 2021-06-28 US US17/360,618 patent/US20220110935A1/en not_active Abandoned
-
2022
- 2022-11-28 JP JP2022189239A patent/JP7668777B2/ja active Active
-
2024
- 2024-03-22 AU AU2024201871A patent/AU2024201871A1/en active Pending
- 2024-11-11 JP JP2024196985A patent/JP2025024064A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS64778B1 (sr) | Lečenje raka | |
| TWI798199B (zh) | 癌症治療 | |
| US20190192522A1 (en) | Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors | |
| TW202027746A (zh) | 用於治療三陰性乳癌之組合療法 | |
| TW201726136A (zh) | 一種ｅｇｆｒ／ｈｅｒ２受體酪氨酸激酶抑制劑在製備治療ｈｅｒ２突變癌症藥物中的用途 | |
| CA3123377A1 (en) | Extended low dose regimens for mdm2 inhibitors | |
| TWI863962B (zh) | 癌症治療 | |
| HK40103983A (en) | Cancer treatment | |
| HK40013982A (en) | Cancer treatment | |
| HK40018978A (en) | Cancer treatment | |
| HK40018978B (en) | Cancer treatment | |
| WO2022191870A1 (en) | Treating cancer in patient having co-occurring genetic alteration in fgfr2 and a cancer driver gene |